Acute effects of oral olanzapine treatment on the expression of fatty acid and cholesterol metabolism-related gene in rats

Life Sciences

Volumn 128, Issue , 2015, Pages 72-78

  Liu, Xuemei ^a,b   Deng, Chao ^c   Cao, Shuang ^b   Gong, Jingwen ^b   Wang, Bo Chu ^a   Hu, Chang Hua ^b,d  

^a CHONGQING UNIVERSITY   (China)

^b SOUTHWEST UNIVERSITY   (China)

^c UNIVERSITY OF WOLLONGONG   (Australia)

^d Research Center   (China)

Author keywords

Dyslipidemia; Olanzapine; Pharmacokinetics; SREBPs

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; OLANZAPINE; STEROL REGULATORY ELEMENT BINDING PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRIACYLGLYCEROL; BENZODIAZEPINE DERIVATIVE; FATTY ACID; MESSENGER RNA; NEUROLEPTIC AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; ELIMINATION HALF-LIFE; ELIMINATION RATE CONSTANT; FATTY ACID SYNTHESIS; FEMALE; GENE EXPRESSION; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; RAT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TRIACYLGLYCEROL BLOOD LEVEL; WHITE ADIPOSE TISSUE; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; GENETICS; LIVER; METABOLISM; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT;

RATTUS;

ADIPOSE TISSUE, WHITE; ADMINISTRATION, ORAL; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIOSYNTHETIC PATHWAYS; CHOLESTEROL; FATTY ACIDS; FEMALE; GENE EXPRESSION; LIVER; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

EID: 84925855714     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2015.01.033     Document Type: Article

References (51)

1. D.B. Allison, J.W. Newcomer, A.L. Dunn, J.A. Blumenthal, and A.N. Fabricatore et al. Obesity among those with mental disorders: a National Institute of Mental Health Meeting Report Am. J. Prev. Med. 36 2009 341 350
2. M. Aravagiri, Y. Teper, and S.R. Marder Pharmacokinetics and tissue distribution of olanzapine in rats Biopharm. Drug Dispos. 20 1999 369 377
3. A.J. Azzaro, J. Ziemniak, E. Kemper, B.J. Campbell, and C. VanDenBerg Selegiline transdermal system: an examination of the potential for CYP450-dependent pharmacokinetic interactions with 3 psychotropic medications J. Clin. Pharmacol. 47 2007 146 158
4. A.B. Birkenaes, K.I. Birkeland, J.A. Engh, A. Faerden, and H. Jonsdottir et al. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions J. Clin. Psychopharmacol. 28 2008 132 137
5. C. Correl, M. de Hert, J. Detraux, R. Van Winkel, and W. Yu Metabolic and cardiovascular adverse effects associated with antipsychotic drugs Nat. Rev. Endocrinol. 8 2012 114
6. C.U. Correll From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics Eur. Psychiatry 25 Supplement 2 2010 S12 S21
7. D. Cui, Y. Li, M. Lian, F. Yang, and Q. Meng Development of a simple and stability-indicating RP-HPLC method for determining olanzapine and related impurities generated in the preparative process Analyst 136 2011 3149 3156
8. C. Deng Effects of antipsychotic medications on appetite, weight, and insulin resistance Endocrinol. Metab. Clin. N. Am. 42 2013 545 563
9. C. Deng, J. Lian, N. Pai, and X.F. Huang Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model J. Psychopharmacol. 26 2012 1271 1279
10. FDA Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers 2005 http://www.fda.gov/cder/guidance/index.htm
11. M.J. Fell, J.C. Neill, N. Anjum, L.M. Peltola, and K.M. Marshall Investigation into the influence of a high fat diet on antipsychotic-induced weight gain in female rats J. Psychopharmacol. 22 2008 182 186
12. J. Ferno, M.B. Raeder, A.O. Vik-Mo, S. Skrede, and M. Glambek et al. Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? Pharmacogenomics J. 5 2005 298 304
13. J. Ferno, S. Skrede, A.O. Vik-Mo, G. Jassim, S. Le Hellard, and V.M. Steen Lipogenic effects of psychotropic drugs: focus on the SREBP system Front. Biosci. (Landmark Ed.) 16 2011 49 60
14. J. Ferno, A.O. Vik-Mo, G. Jassim, B. Havik, and K. Berge et al. Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver Psychopharmacology 203 2009 73 84
15. E. Fliers, F. Kreier, P.J. Voshol, L.M. Havekes, and H.P. Sauerwein et al. White adipose tissue: getting nervous J. Neuroendocrinol. 15 2003 1005 1010
16. M. Foretz, C. Pacot, I. Dugail, P. Lemarchand, and C. Guichard et al. ADD1/SREBP-1c is required in the activation of hepatic lipogenic gene expression by glucose Mol. Cell. Biol. 19 1999 3760 3768
17. G. Gervasini, M.J. Caballero, J.A. Carrillo, and J. Benitez Comparative cytochrome p450 in vitro inhibition by atypical antipsychotic drugs ISRN Pharmacol. 2013 2013 792456
18. Y. Hu, E. Kutscher, and G.E. Davies Berberine inhibits SREBP-1-related clozapine and risperidone induced adipogenesis in 3T3-L1 cells Phytother. Res. 24 2010 1831 1838
19. G. Jassim, S. Skrede, M.J. Vazquez, H. Wergedal, and A.O. Vik-Mo et al. Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat Psychopharmacology 219 2012 783 794
20. J.T. Kantrowitz, and L. Citrome Olanzapine: review of safety 2008 Expert Opin. Drug Saf. 7 2008 761 769
21. D.L. Kelly, R.R. Conley, and C.A. Tamminga Differential olanzapine plasma concentrations by sex in a fixed-dose study Schizophr. Res. 40 1999 101 104
22. J.B. Kim, and B.M. Spiegelman ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism Genes Dev. 10 1996 1096 1107
23. J. Kotzka, and D. Muller-Wieland Sterol regulatory element-binding protein (SREBP)-1: gene regulatory target for insulin resistance? Expert Opin. Ther. Targets 8 2004 141 149
24. F. Kreier, E. Fliers, P.J. Voshol, C.G. Van Eden, and L.M. Havekes et al. Selective parasympathetic innervation of subcutaneous and intra-abdominal fat - functional implications J. Clin. Invest. 110 2002 1243 1250
25. E. Lauressergues, F. Martin, A. Helleboid, E. Bouchaert, and D. Cussac et al. Overweight induced by chronic risperidone exposure is correlated with overexpression of the SREBP-1c and FAS genes in mouse liver Naunyn Schmiedeberg's Arch. Pharmacol. 383 2011 423 436
26. E. Lauressergues, B. Staels, K. Valeille, Z. Majd, and D.W. Hum et al. Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes Naunyn Schmiedeberg's Arch. Pharmacol. 381 2010 427 439
27. J. Lian, X.F. Huang, N. Pai, and C. Deng Effects of olanzapine and betahistine co-treatment on serotonin transporter, 5-HT2A and dopamine D2 receptor binding density Prog. Neuro-Psychopharmacol. Biol. Psychiatry 47 2013 62 68
28. J. Lian, X.F. Huang, N. Pai, and C. Deng Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic, NPY and AMPK pathways Psychoneuroendocrinology 48 2014 77 86
29. S. Mann, A. Chintoh, A. Giacca, P. Fletcher, and J. Nobrega et al. Chronic olanzapine administration in rats: effect of route of administration on weight, food intake and body composition Pharmacol. Biochem. Behav. 103 2013 717 722
30. H.Y. Meltzer Update on typical and atypical antipsychotic drugs Annu. Rev. Med. 64 2013 393 406
31. C. Morin, S. Proteau, E. Rousseau, and J. Brayden Organ-cultured airway explants: a new model of airway hyperresponsiveness Exp. Lung Res. 31 2005 719 744
32. H.A. Nasrallah Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles Mol. Psychiatry 13 2008 27 35
33. K.J. Oh, J. Park, S.Y. Lee, I. Hwang, and J.B. Kim et al. Atypical antipsychotic drugs perturb AMPK-dependent regulation of hepatic lipid metabolism Am. J. Physiol. Endocrinol. Metab. 300 2011 E624 E632
34. J. Pearce Fatty acid synthesis in liver and adipose tissue Proc. Nutr. Soc. 42 1983 263 271
35. M.B. Raeder, J. Ferno, A.O. Vik-Mo, and V.M. Steen SREBP activation by antipsychotic- and antidepressant-drugs in cultured human liver cells: relevance for metabolic side-effects? Mol. Cell. Biochem. 289 2006 167 173
36. S. Reagan-Shaw, M. Nihal, and N. Ahmad Dose translation from animal to human studies revisited FASEB J. 22 2008 659 661
37. B. Sadibasic, A. Macic-Dzankovic, A. Sabic, B. Torlak, G. Lastric, and A. Custovic The incidence of dyslipidemia (hypertriglyceridemia and hypercholesterolemia) in patients treated with the new generation of antipsychotic drugs compared to conventional therapy Med. Glas. (Zenica) 11 2014 350 355
38. A.K. Sarvari, Z. Vereb, I.P. Uray, L. Fesus, and Z. Balajthy Atypical antipsychotics induce both proinflammatory and adipogenic gene expression in human adipocytes in vitro Biochem. Biophys. Res. Commun. 450 2014 1383 1389
39. G. Schmitz, and T. Langmann Structure, function and regulation of the ABC1 gene product Curr. Opin. Lipidol. 12 2001 129 140
40. A.L. Sertie, A.M. Suzuki, R.A. Sertie, S. Andreotti, and F.B. Lima et al. Effects of antipsychotics with different weight gain liabilities on human in vitro models of adipose tissue differentiation and metabolism Prog. Neuro-Psychopharmacol. Biol. Psychiatry 35 2011 1884 1890
41. J.J. Sheehan, J.K. Sliwa, J.C. Amatniek, A. Grinspan, and C.M. Canuso Atypical antipsychotic metabolism and excretion Curr. Drug Metab. 11 2010 516 525
42. H. Shimano Sterol regulatory element-binding proteins (SREBPs): transcriptional regulators of lipid synthetic genes Prog. Lipid Res. 40 2001 439 452
43. S. Skrede, J. Ferno, M.J. Vazquez, S. Fjaer, and T. Pavlin et al. Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats Int. J. Neuropsychopharmacol. 15 2012 163 179
44. S.M. Stahl, L. Mignon, and J.M. Meyer Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr. Scand. 119 2009 171 179
45. J. Swierczynski, E. Goyke, L. Wach, A. Pankiewicz, and Z. Kochan et al. Comparative study of the lipogenic potential of human and rat adipose tissue Metabolism 49 2000 594 599
46. E.M. van der Zwaal, M.C. Luijendijk, R.A. Adan, and S.E. la Fleur Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution Eur. J. Pharmacol. 585 2008 130 136
47. K. Weston-Green, X.F. Huang, and C. Deng Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats Behav. Brain Res. 217 2011 337 346
48. K. Weston-Green, X.F. Huang, J. Lian, and C. Deng Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels Eur. Neuropsychopharmacol. 22 2012 364 373
49. L.H. Yang, T.M. Chen, S.T. Yu, and Y.H. Chen Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells Pharmacol. Res. 56 2007 202 208
50. T.T. Yang, C.K. Chang, C.W. Tsao, Y.M. Hsu, C.T. Hsu, and J.T. Cheng Activation of muscarinic M-3 receptor may decrease glucose uptake and lipolysis in adipose tissue of rats Neurosci. Lett. 451 2009 57 59
51. M.C. Mauri, L.S. Volonteri, A. Colasanti, A. Fiorentini, I.F. De Gaspari, and S.R. Bareggi Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response Clin Pharmacokinet 46 2007 359 388